Cargando…
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model
BACKGROUND: The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an ultra-orphan disease threshold of 2/100,000 population used in England...
Autores principales: | Starczewska Amelio, Justyna M, Cid Ruzafa, Javier, Desai, Kamal, Tzivelekis, Spiros, Muston, Dominic, Khalid, Javaria Mona, Ashman, Philip, Maguire, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039646/ https://www.ncbi.nlm.nih.gov/pubmed/24884940 http://dx.doi.org/10.1186/1471-2407-14-364 |
Ejemplares similares
-
The radiology of gastrointestinal stromal tumours (GIST)
por: Michael King, D
Publicado: (2005) -
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010) -
Gastrointestinal Stromal Tumours (GISTs) with KRAS Mutation: A Rare but Important Subset of GISTs
por: Mullen, Dorinda, et al.
Publicado: (2023) -
A Guideline for the Management of Gastrointestinal Stromal
Tumour (GIST)
por: Judson, Ian, et al.
Publicado: (2002) -
An unusual presentation of a Gastrointestinal stromal tumour (GIST)
por: John, Solomon KP, et al.
Publicado: (2007)